Changes in Beneficial Ownership · 4
Dyne Therapeutics, Inc.
DYNNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
ownership.xml
Filing details
- Report period
- 2026-10-20
- Issuer
- Dyne Therapeutics, Inc.
- Issuer CIK
- 0001818794
- Trading symbol
- DYN
Reporting owner 1
- Name
- Kerr Douglas
- Reporting owner CIK
- 0001814189
- Relationship
- Officer
- Officer title
- Head of R&D and CMO
- Address
- C/O DYNE THERAPEUTICS, INC., 1560 TRAPELO ROAD, WALTHAM, MA, 02451
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock | 2026-10-20 | A · Form 4 | 8,000[F1] | A | 0 | 170,564[F2] | D |
Table key
- A · Form 4
- Acquisition by grant, award or otherwise under Rule 16b-3(d)
- A
- Acquired
- D
- Direct
Derivative transactions
| Security | Conversion / exercise price (USD) | Transaction date | Code | Amount | A / D | Price (USD) | Exercisable | Expires | Underlying security | Underlying shares | Owned after | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy) | 16.27 | 2026-10-20 | A · Form 4 | 12,000 | A | 0 | [F3] | 2036-10-19 | Common Stock | 12,000 | 12,000 | D |
Table key
- A · Form 4
- Acquisition by grant, award or otherwise under Rule 16b-3(d)
- A
- Acquired
- D
- Direct
Footnotes
- F1
- Consists of shares of Common Stock issuable under 8,000 restricted stock units ("RSUs"). Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in equal quarterly installments over four years with the first installment vesting on January 20, 2027.↩ 1
- F2
- Includes 133,126 unvested RSUs.↩ 1
- F3
- This option was granted on October 20, 2026. The shares underlying the option are scheduled to vest over four years in equal monthly installments through October 20, 2030.↩ 1
Signature 1
- Signed
- /s/ Ron Caponigro, Attorney-in-Fact
- Date
- 2026-10-22
Company context
Dyne Therapeutics is focused on delivering functional improvement for people living with genetically driven neuromuscular diseases. We are developing therapeutics that target muscle and the central nervous system (CNS) to address the root cause of disease. The company is advancing clinical programs for Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1) as well as preclinical programs for facioscapulohumeral muscular dystrophy (FSHD), Pompe disease and multiple DMD mutations. At Dyne, we are on a mission to deliver functional improvement for individuals, families and communities. Learn more at https://www.dyne-tx.com/, and follow us on X, LinkedIn and Facebook.